Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
1000
Trial Sponsor
Clinical Trial Start Date
August 5, 2024
0Primary Completion Date
February 15, 2025
0Study Completion Date
February 15, 2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Interventional Trial Phase
Phase 30
Phase 20
Official Name
A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine0
Last Updated
May 10, 2024
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
NVX-CoV2705 Vaccine0
Study summary
Phase 3 study assessing the safety and effectiveness of a single dose of a SARS-CoV-2 nanoparticle vaccine (NVX CoV2705) adjuvanted with Matrix-M™ in previously vaccinated adults. About 100 participants will receive the vaccine and be monitored for safety and immune response for up to 35 days post-vaccination.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
